Ann: VLA to Present CAVATAK Bladder and Other Results at Conf., page-2

Bell Potter's report from 2nd June

a snip

"Upgrade To Target Price, Maintain Buy Following positive announcements from the CALM study and interim results from the tumour micro-analysis, in our view the risk attached to VLA is decreased. There is now a sound foundation to assume the drug has meaningful efficacy. In addition the likely approval of T-Vec later this year provides additional comfort that oncolytic virotherapy will have a place in the treatment landscape for melanoma and potentially other indications. For these reasons we upgrade our target price to $0.96"